{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:23:46Z","timestamp":1778261026727,"version":"3.51.4"},"reference-count":17,"publisher":"Texas Heart Institute Journal","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p>We report the case of an 82-year-old man in whom hemorrhagic pericardial effusion occurred one week after pacemaker implantation, while he was taking apixaban. Few therapies exist for reversing the anti-Xa effect of apixaban. To reverse anticoagulation, our patient underwent plasma exchange, which facilitated pericardiocentesis and prevented possible surgical intervention. To our knowledge, this is the first report of the use of plasmapheresis to reverse the anticoagulant effect of apixaban.<\/jats:p>","DOI":"10.14503\/thij-14-4424","type":"journal-article","created":{"date-parts":[[2015,8,3]],"date-time":"2015-08-03T13:22:06Z","timestamp":1438608126000},"page":"377-380","source":"Crossref","is-referenced-by-count":13,"title":["Plasma Exchange for Urgent Apixaban Reversal in a Case of Hemorrhagic Tamponade after Pacemaker Implantation"],"prefix":"10.14503","volume":"42","author":[{"given":"Wilson W.","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith A.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Seger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5628","reference":[{"issue":"11","key":"i0730-2347-42-4-377-b1","series-title":"N Engl J Med","first-page":"981","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","year":"2011","unstructured":"Granger\n              CB, \n            \n              Alexander\n              JH, \n            \n              McMurray\n              JJ, \n            \n              Lopes\n              RD, \n            \n              Hylek\n              EM, \n            \n              Hanna\n              M, \n          \n          et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med2011;365(11):981\u201392."},{"issue":"6","key":"i0730-2347-42-4-377-b2","series-title":"Curr Opin Hematol","first-page":"552","article-title":"Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects","volume":"20","year":"2013","unstructured":"Yates\n              S, \n            \n              Sarode\n              R.\n            \n          \n          Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects. Curr Opin Hematol2013;20(6):552\u20137."},{"issue":"2","key":"i0730-2347-42-4-377-b3","series-title":"Am J Cardiol","first-page":"223","article-title":"Proper management of pericardial tamponade as a late complication of implantable cardiac device placement","volume":"98","year":"2006","unstructured":"Polin\n              GM, \n            \n              Zado\n              E, \n            \n              Nayak\n              H, \n            \n              Cooper\n              JM, \n            \n              Russo\n              AM, \n            \n              Dixit\n              S, \n          \n          et al. Proper management of pericardial tamponade as a late complication of implantable cardiac device placement. Am J Cardiol2006;98(2):223\u20135."},{"issue":"3","key":"i0730-2347-42-4-377-b4","series-title":"J Thromb Haemost","first-page":"320","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","year":"2014","unstructured":"van der Hulle\n              T, \n            \n              Kooiman\n              J, \n            \n              den Exter\n              PL, \n            \n              Dekkers\n              OM, \n            \n              Klok\n              FA, \n            \n              Huisman\n              MV.\n            \n          \n          Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost2014;12(3):320\u20138."},{"issue":"3","key":"i0730-2347-42-4-377-b5","series-title":"J Gen Intern Med","first-page":"438","article-title":"Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis","volume":"29","year":"2014","unstructured":"You\n              JH.\n            \n          \n          Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis. J Gen Intern Med2014;29(3):438\u201346."},{"issue":"6\u20137","key":"i0730-2347-42-4-377-b6","series-title":"Arch Cardiovasc Dis","first-page":"382","article-title":"Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013","volume":"106","year":"2013","unstructured":"Pernod\n              G, \n            \n              Albaladejo\n              P, \n            \n              Godier\n              A, \n            \n              Samama\n              CM, \n            \n              Susen\n              S, \n            \n              Gruel\n              Y, \n          \n          et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis2013;106 (6\u20137):382\u201393."},{"issue":"13","key":"i0730-2347-42-4-377-b7","series-title":"Am J Health Syst Pharm","first-page":"1113","article-title":"Apixaban: a novel oral inhibitor of factor Xa","volume":"69","year":"2012","unstructured":"Nutescu\n              E.\n            \n          \n          Apixaban: a novel oral inhibitor of factor Xa. Am J Health Syst Pharm2012;69(13):1113\u201326."},{"issue":"2","key":"i0730-2347-42-4-377-b8","series-title":"Am J Cardiovasc Drugs","first-page":"147","article-title":"Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects","volume":"14","year":"2014","unstructured":"Wang\n              X, \n            \n              Mondal\n              S, \n            \n              Wang\n              J, \n            \n              Tirucherai\n              G, \n            \n              Zhang\n              D, \n            \n              Boyd\n              RA, \n            \n              Frost\n              C.\n            \n          \n          Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs2014;14(2):147\u201354."},{"issue":"5","key":"i0730-2347-42-4-377-b9","series-title":"Europace","first-page":"625","article-title":"European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","year":"2013","unstructured":"Heidbuchel\n              H, \n            \n              Verhamme\n              P, \n            \n              Alings\n              M, \n            \n              Antz\n              M, \n            \n              Hacke\n              W, \n            \n              Oldgren\n              J, \n          \n          et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace2013;15(5): 625\u201351."},{"issue":"3","key":"i0730-2347-42-4-377-b10","series-title":"Blood Transfus","first-page":"149","article-title":"Prothrombin complex concentrates: an update","volume":"8","year":"2010","unstructured":"Franchini\n              M, \n            \n              Lippi\n              G.\n            \n          \n          Prothrombin complex concentrates: an update. Blood Transfus2010;8(3):149\u201354."},{"issue":"7","key":"i0730-2347-42-4-377-b11","series-title":"Cleve Clin J Med","first-page":"443","article-title":"Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban","volume":"80","year":"2013","unstructured":"Fawole\n              A, \n            \n              Daw\n              HA, \n            \n              Crowther\n              MA.\n            \n          \n          Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med2013;80(7):443\u201351."},{"issue":"4","key":"i0730-2347-42-4-377-b12","series-title":"Nat Med","first-page":"446","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","year":"2013","unstructured":"Lu\n              G, \n            \n              DeGuzman\n              FR, \n            \n              Hollenbach\n              SJ, \n            \n              Karbarz\n              MJ, \n            \n              Abe\n              K, \n            \n              Lee\n              G, \n          \n          et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med2013;19(4):446\u201351."},{"issue":"2","key":"i0730-2347-42-4-377-b13","series-title":"J Thromb Thrombolysis","first-page":"183","article-title":"Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor","volume":"32","year":"2011","unstructured":"Becker\n              RC, \n            \n              Yang\n              H, \n            \n              Barrett\n              Y, \n            \n              Mohan\n              P, \n            \n              Wang\n              J, \n            \n              Wallentin\n              L, \n            \n              Alexander\n              JH.\n            \n          \n          Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis2011;32(2):183\u20137."},{"issue":"2","key":"i0730-2347-42-4-377-b14","series-title":"Thromb Haemost","first-page":"240","article-title":"Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multi-centre French GEHT study","volume":"111","year":"2014","unstructured":"Gouin-Thibault\n              I, \n            \n              Flaujac\n              C, \n            \n              Delavenne\n              X, \n            \n              Quenet\n              S, \n            \n              Horellou\n              MH, \n            \n              Laporte\n              S, \n          \n          et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multi-centre French GEHT study. Thromb Haemost2014;111(2): 240\u20138."},{"key":"i0730-2347-42-4-377-b15","series-title":"Clin Pharmacol","first-page":"177","article-title":"Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [published erratum appears in Clin Pharmacol 2014;6:61]","volume":"5","year":"2013","unstructured":"Cui\n              Y, \n            \n              Song\n              Y, \n            \n              Wang\n              J, \n            \n              Yu\n              Z, \n            \n              Schuster\n              A, \n            \n              Barrett\n              YC, \n            \n              Frost\n              C.\n            \n          \n          Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [published erratum appears in Clin Pharmacol 2014;6:61]. Clin Pharmacol2013;5:177\u201384."},{"issue":"6","key":"i0730-2347-42-4-377-b16","series-title":"Am J Kidney Dis","first-page":"817","article-title":"Therapeutic plasma exchange: complications and management","volume":"23","year":"1994","unstructured":"Mokrzycki\n              MH, \n            \n              Kaplan\n              AA.\n            \n          \n          Therapeutic plasma exchange: complications and management. Am J Kidney Dis1994;23 (6):817\u201327."},{"key":"i0730-2347-42-4-377-b17","series-title":"Neurology","first-page":"PD6.008","article-title":"Costs and charges for plasma exchange (PLEX) versus intravenous immunoglobulin (IVIg) in the treatment of neuromuscular disease","volume":"78","year":"2012","unstructured":"Robinson\n              J, \n            \n              Eccher\n              M, \n            \n              Bengier\n              A, \n            \n              Liberman\n              J.\n            \n          \n          Costs and charges for plasma exchange (PLEX) versus intravenous immunoglobulin (IVIg) in the treatment of neuromuscular disease. Neurology2012;78:PD6.008."}],"container-title":["Texas Heart Institute Journal"],"original-title":[],"link":[{"URL":"https:\/\/thij.kglmeridian.com\/view\/journals\/thij\/42\/4\/article-p377.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/thij\/article-pdf\/42\/4\/377\/2324983\/thij-14-4424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thij.kglmeridian.com\/downloadpdf\/journals\/thij\/42\/4\/article-p377.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thij.kglmeridian.com\/downloadpdf\/journals\/thij\/42\/4\/article-p377.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T15:30:08Z","timestamp":1730993408000},"score":1,"resource":{"primary":{"URL":"https:\/\/thij.kglmeridian.com\/view\/journals\/thij\/42\/4\/article-p377.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":17,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.14503\/thij-14-4424","relation":{},"ISSN":["0730-2347","1526-6702"],"issn-type":[{"value":"0730-2347","type":"print"},{"value":"1526-6702","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}